Maria Silvia Cona

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

Luca Cantini, Giulia Mentrasti, Gian Luigi Russo et al. · ESMO Open · 2022 · 65 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer

Claudio Vernieri, Alessia Mennitto, Michele Prisciandaro et al. · Scientific Reports · 2018 · 55 citations · Full text

Medicine, Oncology, Pharmacology +15

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study

L. Provenzano, M.V. Dieci, G. Curigliano et al. · Annals of Oncology · 2025 · 33 citations · Full text

Medicine, Oncology, Pharmacology +16

Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study

Giulia Mentrasti, Luca Cantini, Clizia Zichi et al. · The Oncologist · 2022 · 32 citations · Full text

Medicine, Oncology, Cancer Screening +16

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies

Maria Silvia Cona, Mara Lecchi, Sara Cresta et al. · Cancers · 2019 · 30 citations · Full text

Medicine, Immunology, Oncology +17